Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChromaVision/Ventana to market HPV (Human Papilloma Virus) test:

This article was originally published in Clinica

Executive Summary

ChromaVision Medical Systems and Ventana Medical Systems are to co-market an automated staining and imaging test for human papillomavirus. The test will combine ChromaVision's automated cellular imaging system (ACIS) and Ventana's automated staining systems and reagents to offer direct visual interpretation of cellular analyses. Until now ChromaVision has concentrated on oncologic tests. It is estimated that the US market alone is some 3.5 million HIV tests per year.

Topics

UsernamePublicRestriction

Register

MT068392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel